SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Array Biopharma, Inc
ARRY 8.995+1.6%Jan 9 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (202)10/21/2013 9:55:44 AM
From: scaram(o)uche  Read Replies (2) of 321
 
>> Next, we might watch for a telegraphed combo, 162 and LEE011 (CDK4/6 inhibitor) <<

Ms. Church is out tweeting for ASH, and she says....

Sally Church ?@MaverickNY 15h
LEE011 + BYL719 leads to tumour regression in PIK3CA mut breast cancer models #targets13 @AdamsLisa

Sally Church ?@MaverickNY 15h
LEE011 will also be combined with MEK162 in NRAS mut melanomas and with LGX818 to prevent emergence of resistance #targets13 v interesting

Sally Church ?@MaverickNY 15h
Whoa, IC50 for NVS new CDK4/6 inhibitor LEE011 are very low! Read <0.05. Being evaluated in pediatric tumours #targets13
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext